MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 154 filers reported holding MERSANA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,022 | -59.0% | 24,427 | +6.3% | 0.00% | -100.0% |
| Q2 2023 | $75,594 | -20.5% | 22,977 | -0.7% | 0.00% | 0.0% |
| Q1 2023 | $95,056 | -26.0% | 23,128 | +5.4% | 0.00% | 0.0% |
| Q4 2022 | $128,539 | -10.1% | 21,935 | +4.0% | 0.00% | 0.0% |
| Q3 2022 | $143,000 | +50.5% | 21,086 | +3.0% | 0.00% | 0.0% |
| Q2 2022 | $95,000 | +53.2% | 20,481 | +31.7% | 0.00% | – |
| Q1 2022 | $62,000 | -35.4% | 15,551 | +0.6% | 0.00% | -100.0% |
| Q4 2021 | $96,000 | -32.9% | 15,451 | +1.9% | 0.00% | 0.0% |
| Q3 2021 | $143,000 | -29.2% | 15,158 | +1.8% | 0.00% | -50.0% |
| Q2 2021 | $202,000 | -21.7% | 14,896 | -6.6% | 0.00% | 0.0% |
| Q1 2021 | $258,000 | -38.9% | 15,952 | +0.5% | 0.00% | -50.0% |
| Q4 2020 | $422,000 | +47.0% | 15,873 | +2.9% | 0.00% | +33.3% |
| Q3 2020 | $287,000 | +23.2% | 15,423 | +54.6% | 0.00% | 0.0% |
| Q2 2020 | $233,000 | – | 9,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $28,503,484 | 2.94% |
| Logos Global Management LP | 2,800,000 | $9,212,000 | 1.25% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,100,000 | $3,619,000 | 1.12% |
| 5AM Venture Management, LLC | 1,305,000 | $4,293,450 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,000,000 | $3,290,000 | 1.02% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $2,975,042 | 0.93% |
| Sarissa Capital Management LP | 2,632,900 | $8,662,241 | 0.86% |
| DAFNA Capital Management LLC | 810,845 | $2,667,680 | 0.73% |
| Tri Locum Partners LP | 428,307 | $1,409,130 | 0.52% |
| Avidity Partners Management LP | 3,790,000 | $12,469,100 | 0.44% |